康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

未开盘 08-27 16:08:31

101.200

+7.000

+7.43%

最高101.600	最低93.950	成交量1,734万
今开94.750	昨收94.200	日振幅8.12%
总市值932.05亿	流通市值932.05亿	总股本9.21亿
成交额17.17亿	换手率1.88%	流通股本9.21亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":101.2,"timestamp":1787818111008,"preClose":94.2,"halted":0,"volume":17342389,"delay":0,"changeRate":0.07430997876857749,"floatShares":921000000,"shares":921000000,"eps":-1.4380105766233973,"marketStatus":"未开盘","change":7,"latestTime":"08-27 16:08:31","open":94.75,"high":101.6,"low":93.95,"amount":1716551198,"amplitude":0.08121,"askPrice":101.3,"askSize":4000,"bidPrice":101.2,"bidSize":4000,"shortable":3,"etf":0,"ttmEps":-1.4380105766233973,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":0,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":94.2,"openAndCloseTimeList":[[1787794200000,1787803200000],[1787806800000,1787817600000]],"volumeRatio":1.1522853294849607,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.1501,"impliedVolPercentile":0.0134},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2662808658","title":"康方生物(09926.HK)中期亏损为4.47亿元 同比收窄约24.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662808658","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662808658?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:27","pubTimestamp":1787840823,"startTime":"0","endTime":"0","summary":"格隆汇8月27日丨康方生物(09926.HK)发布截至2026年6月30日止六个月之中期业绩。2026年上半年，集团总收入为人民币18.06亿元，同比增长27.92%。集团的亏损为人民币4.47亿元，同比收窄约24.0%。每股基本亏损0.46元。\r\n\r\n　　集团收入的构成包括商业销售收入及商业授权收入。2026年上半年商业销售收入为人民币1,803.2百万元，2025年上半年为人民币1,401.6百万元，同比增长28.65%。2026年上半年商业授权收入为人民币2.5百万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260827/32350719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IE00B543WZ88.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0348735423.USD","LU2476274308.USD","LU0348784397.USD","LU2778985437.USD","BK1574","LU1961090484.USD","LU0348825331.USD","LU0348783233.USD","LU0348827113.USD","LU0561508036.HKD","LU0417516738.SGD","LU2399975544.HKD","LU2488822045.USD","LU0348766576.USD","LU0540923850.HKD","LU1794554557.SGD","LU0417516571.SGD","LU1720050803.USD","KURE","09926","LU0348767384.USD","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662855620","title":"康方生物(09926.HK)发布中期业绩 收入同比增加27.92%至18.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662855620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662855620?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:09","pubTimestamp":1787839794,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348766576.USD","LU2399975544.HKD","LU0348783233.USD","LU1720050803.USD","LU0540923850.HKD","LU0348825331.USD","LU0417516738.SGD","LU0348767384.USD","09926","LU0417516571.SGD","BK1161","IE00BPRC5H50.USD","KURE","LU2488822045.USD","LU0348784397.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348735423.USD","LU0634319403.HKD","LU1961090484.USD","LU2476274720.SGD","LU0561508036.HKD","LU1794554557.SGD","LU2778985437.USD","BK1574","LU0348827113.USD","LU2476274308.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119205193","title":"康方生物2026年中期财报：营收18.06亿元，经调整净亏损4.47亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119205193","media":"公告速递","labels":["SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119205193?lang=zh_cn&edition=full","pubTime":"2026-08-27 22:07","pubTimestamp":1787839625,"startTime":"0","endTime":"0","summary":"截至2026年6月30日，康方生物实现总收入18.06亿元，主要由核心商业销售带动。其中，商业销售收入为18.03亿元，同比增长28.65%；此外，商业授权收入约0.03亿元。报告期内，经调整净亏损4.47亿元，较去年同期的5.88亿元收窄了1.41亿元。经营活动所产生的现金流由去年同期的净流出转为净流入约2.90亿元，财务状况进一步改善。销售及营销费用为7.86亿元，费用率为43.56%，对比去年同期的47.80%有所下降。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物2026年中期财报：营收18.06亿元，经调整净亏损4.47亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2662240147","title":"康方生物盘中涨超6% 国信证券给予“优于大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662240147","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662240147?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:57","pubTimestamp":1787799420,"startTime":"0","endTime":"0","summary":"模拟交易客户端康方生物盘中涨超6%，截至发稿，股价上涨2.34%，现报96.40港元，成交额6.86亿港元。国信证券发布研报称，康方生物的核心产品依沃西在今年取得重要的临床进展，在HARMONi-6临床中取得显著的OS获益之后，此次HARMONi-GI1是首次在肺癌之外获得阳性结果的3期临床，进一步展示了依沃西在泛瘤种中的潜力和优势。康方生物具备全球化的研发能力，产品的大适应症在国内纳入医保预计将快速放量，维持盈利预测，给予“优于大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-27/doc-iniptnuz5783320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002736","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662470721","title":"港股异动 | 康方生物(09926.HK)再涨超6% 依沃西联合化疗一线治疗胆道癌III期达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2662470721","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662470721?lang=zh_cn&edition=full","pubTime":"2026-08-27 10:02","pubTimestamp":1787796171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","BK1574","LU0348825331.USD","LU0417516902.SGD","LU1720050803.USD","LU2778985437.USD","LU2488822045.USD","LU2476274308.USD","IE00BPRC5H50.USD","LU1961090484.USD","LU0348783233.USD","LU1794554557.SGD","09926","LU0348766576.USD","LU0348827113.USD","IE00B543WZ88.USD","KURE","BK1161","LU0540923850.HKD","LU0348735423.USD","LU2399975544.HKD","LU2476274720.SGD","LU0417516738.SGD","LU0634319403.HKD","LU0417516571.SGD","LU0348784397.USD","LU0348767384.USD","LU0561508036.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133902044","title":"异动解读｜康方生物盘中上涨3.03%，依沃西胆道癌III期达主要终点叠加中期业绩发布日催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1133902044","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133902044?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:43","pubTimestamp":1787794985,"startTime":"0","endTime":"0","summary":"8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验，标志着依沃西从肺癌拓展至消化道肿瘤。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物盘中上涨，依沃西胆道癌III期达主要终点","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662729977","title":"【券商聚焦】国投证券：创新药有望开启新一轮高景气周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662729977","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662729977?lang=zh_cn&edition=full","pubTime":"2026-08-27 09:29","pubTimestamp":1787794154,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国投证券研究指，医药景气新周期背景下，国内创新药产业链加速崛起。近年国家多举措全链条支持创新药发展，叠加国内得天独厚的人才储备和研发效率等多维优势，国内创新药持续加速崛起且逐步具备全球竞争力。与此同时，海外MNC陆续面临专利悬崖困境，对外采购和扩充创新管线需求与日俱增，国内创新药企顺势而为，以海外授权BD等形式实现创新出海，创新药有望开启新一轮高景气周期。风险提示：产品研发及审批速度低于预期；产品降价超预期风险；海外BD授权不及预期风险；计算及假设不及预期风险。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989630","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","01177","01877","161027","LU0326950275.SGD","01801","02616","KCE","LU1770034418.SGD","LU1807302812.USD","IE00BPRC5H50.USD","SG9999002562.SGD","LU0880133367.SGD","LU0634319403.HKD","LU0348767384.USD","06160","LU0455707207.USD","IE0008369823.USD","BK1589","IBBQ","LU0417516738.SGD","LU0359201612.USD","LU0314109678.HKD","LU1813983027.USD","LU0140636845.USD","KURE","02269","LU1794554557.SGD","LU1969619763.USD","LU0348825331.USD","LU0307460666.USD","LU0516423091.SGD","09926","LU0516422952.EUR","LU0039217434.USD","06978","09688","LNGR","09995","LU2242644610.SGD","LU0051755006.USD","LU0348783233.USD","MEDX","06185","SG9999004220.SGD","01093","LU0463099449.HKD","02142","LU1226287875.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662769717","title":"康方生物盘中涨超9% 依沃西胆道癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2662769717","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662769717?lang=zh_cn&edition=full","pubTime":"2026-08-26 10:25","pubTimestamp":1787711100,"startTime":"0","endTime":"0","summary":"模拟交易客户端康方生物盘中涨超9%，截至发稿，股价上涨6.81%，现报94.85港元，成交额8.14亿港元。此项突破标志着依沃西继在肺癌领域斩获4项III期阳性结果后，再次在其他实体瘤治疗领域取得重要的III期临床研究阳性结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-26/doc-iniprcpu1098416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["III","IE00B5MMRT66.SGD","LU1961090484.USD","BK4134","BK1574","LU2488822045.USD","LU1794554557.SGD","LU0540923850.HKD","LU0634319403.HKD","LU0348827113.USD","LU0561508036.HKD","LU2476274308.USD","LU0348767384.USD","09926","LU0417516902.SGD","IE00B543WZ88.USD","BK1161","LU0348784397.USD","LU0417516738.SGD","LU0348825331.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274720.SGD","KURE","LU2778985437.USD","IE00BPRC5H50.USD","LU1720050803.USD","LU0348766576.USD","LU0348735423.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662766038","title":"港股异动 | 康方生物(09926.HK)早盘涨超8% 依沃西胆道癌III期研究成功 头对头击败度伐利尤","url":"https://stock-news.laohu8.com/highlight/detail?id=2662766038","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662766038?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:43","pubTimestamp":1787708606,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1794554557.SGD","LU1720050803.USD","LU0348783233.USD","LU1961090484.USD","KURE","LU0348766576.USD","LU0348784397.USD","LU0348825331.USD","LU0417516738.SGD","BK1161","LU2476274308.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0540923850.HKD","LU2778985437.USD","09926","LU0348827113.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU0417516571.SGD","BK1574","LU2488822045.USD","LU0561508036.HKD","LU2399975544.HKD","LU0348735423.USD","LU0348767384.USD","IE00B5MMRT66.SGD","LU0634319403.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149905224","title":"港股直击｜创新药股股价齐扬，隔夜美股公司Moderna股价飙升14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149905224","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149905224?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:39","pubTimestamp":1787708343,"startTime":"0","endTime":"0","summary":"港股创新药股股价齐扬，云顶新耀升 8%，康方生物升 7%，药明巨诺升 5%，荣昌生物升 4%。消息面上，隔夜美股生物技术公司莫德纳(Moderna)股价飙升14%，此前巴克莱上调了其目标价，且投资机构Wolfe Research也看好该公司mRNA癌症疫苗的商业潜力。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01952","02126","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662192769","title":"挑战PD-L1“药王”成功，康方生物的PD-1双抗擂台赛从肺癌打到了胆道癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2662192769","media":"第一财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662192769?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:33","pubTimestamp":1787708009,"startTime":"0","endTime":"0","summary":"继头对头挑战默沙东K药物后，康方生物（09926.HK)的PD-1/VEGF双抗依沃西擂台赛还在继续。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608263854239539.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608263854239539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["KURE","LU1169589451.USD","BK1574","LU1961090484.USD","IE00BPRC5H50.USD","LU0634319403.HKD","LU2476274308.USD","LU0348766576.USD","BK1161","IE00B5MMRT66.SGD","LU0348825331.USD","LU2399975544.HKD","LU1169590202.USD","LU1720050803.USD","LU0348783233.USD","LU0561508036.HKD","PD","LU1794554557.SGD","LU0417516571.SGD","LU2778985437.USD","LU0417516738.SGD","LU0417516902.SGD","LU2476274720.SGD","LU0348827113.USD","09926","BK4023","LU2488822045.USD","LU0348735423.USD","LU0348767384.USD","LU0540923850.HKD","IE00B543WZ88.USD","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150980532","title":"异动解读｜康方生物盘中上涨6.64%，依沃西胆道癌III期临床达OS显著阳性终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1150980532","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150980532?lang=zh_cn&edition=full","pubTime":"2026-08-26 09:33","pubTimestamp":1787707994,"startTime":"0","endTime":"0","summary":"8月26日，康方生物盘中上涨6.64%，报94.05港元，成交额1.44亿港元。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验。此外，公司中期业绩将于8月27日发布，依沃西第三适应症已于8月12日获批上市，放量节奏受市场关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物异动拉升，依沃西胆道癌临床达阳性终点","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662768791","title":"康方生物(09926)：依沃西联合化疗对比度伐利尤联合化疗的AK112–309/HARMONi-GI1 III期临床达到OS显著阳性结果，具有统计学显著和重大临床获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2662768791","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662768791?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:40","pubTimestamp":1787701212,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物 发布公告，由本公司自主研发的全球首创双特异性抗体依达方联合化疗方案对比度伐利尤联合化疗方案，用于一线治疗晚期胆道癌的随机、对照、双盲、多中心III期临床研究经独立数据监察委员会评估的预先设定的期中分析结果显示，该研究达到总生存期主要研究终点，取得具有统计学显著和重大临床获益的阳性结果;该研究亦达到无进展生存期与客观缓解率的所有关键次要终点。HARMONi-GI1研究共入组682例受试者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0540923850.HKD","LU0417516571.SGD","LU0348784397.USD","IE00B5MMRT66.SGD","KURE","LU0561508036.HKD","LU2476274720.SGD","09926","LU0348827113.USD","LU0348767384.USD","LU0348735423.USD","LU0348766576.USD","LU0417516902.SGD","BK4134","LU0417516738.SGD","LU0348783233.USD","BK1574","LU1720050803.USD","LU2476274308.USD","BK1161","III","LU1794554557.SGD","LU2778985437.USD","LU0634319403.HKD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU1961090484.USD","LU2488822045.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149263661","title":"康方生物（09926）公布依沃西一线治疗晚期胆道癌III期试验达成OS统计学显著阳性","url":"https://stock-news.laohu8.com/highlight/detail?id=1149263661","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149263661?lang=zh_cn&edition=full","pubTime":"2026-08-26 07:06","pubTimestamp":1787699162,"startTime":"0","endTime":"0","summary":"2026年8月26日，康方生物（09926）发布自愿公告称，公司自主研发的全球首创PD-1/VEGF双特异性抗体依达方®（商品名：依沃西）联合化疗，与度伐利尤联合化疗对比，用于一线治疗晚期胆道癌的随机、对照、双盲、多中心III期临床研究（AK112-309 / HARMONi-GI1，登记号：CTR20243164）在预设的期中分析中达到主要研究终点总生存期（OS）统计学显著且具有重大临床获益的阳性结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168886256","title":"伊沃西单抗联合化疗一线治疗胆道癌显著延长总生存期，Harmoni-Gi1研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1168886256","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168886256?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:01","pubTimestamp":1787691675,"startTime":"0","endTime":"0","summary":"伊沃西单抗联合化疗方案，在晚期胆道癌一线治疗中展现出压倒性的总生存期优势——与度伐利尤单抗联合化疗的对照组相比，疗效差异显著。这一重磅结果来自Harmoni-Gi1关键性III期临床试验，该研究已正式达成其主要终点。数据显示，伊沃西单抗组患者的总生存期获益更为突出，风险比达到统计学显著水平。安全性方面，研究数据显示伊沃西单抗联合化疗的整体安全性特征与既往报告一致，未发现新的安全信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU1720050803.USD","LU2488822045.USD","LU0417516571.SGD","KURE","BK1161","LU0634319403.HKD","LU0417516738.SGD","LU1794554557.SGD","LU0348767384.USD","09926","LU0348825331.USD","LU0348783233.USD","LU2399975544.HKD","IE00BPRC5H50.USD","LU0348735423.USD","LU0348827113.USD","IE00B543WZ88.USD","LU2778985437.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU0348766576.USD","LU2476274308.USD","LU0561508036.HKD","LU1961090484.USD","BK1574","LU0417516902.SGD","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197106600","title":"康方生物Harmoni-Gi1：首个III期研究显示胆道癌总生存期显著优于全球标准疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1197106600","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197106600?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:01","pubTimestamp":1787691673,"startTime":"0","endTime":"0","summary":"康方生物披露了一项重磅临床进展——其Harmoni-Gi1研究成为首个在胆道癌领域展现总生存期显著获益的III期临床试验，且疗效对比对象为当前全球标准治疗方案。康方生物此番公布的成果，意味着Harmoni-Gi1不仅跨过了统计学意义的门槛，更在临床价值层面树立了新的里程碑——相较于全球标准疗法，试验组在总生存期上实现了具有显著差异的改善。康方生物能否借此进一步巩固其在双抗及肿瘤治疗领域的领先地位，值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","BK1161","LU0540923850.HKD","LU0417516902.SGD","LU0417516571.SGD","LU0348784397.USD","LU2488822045.USD","LU0348783233.USD","LU0561508036.HKD","LU0348766576.USD","LU1961090484.USD","LU0348825331.USD","LU2476274720.SGD","LU0348827113.USD","LU1794554557.SGD","LU1720050803.USD","09926","LU0348767384.USD","LU0348735423.USD","LU0634319403.HKD","LU2778985437.USD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00B543WZ88.USD","KURE","BK1574","LU2399975544.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100578137","title":"异动解读｜康方生物盘中上涨3.49%，中期业绩发布在即叠加ADC管线新进展提振情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1100578137","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100578137?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:35","pubTimestamp":1787535354,"startTime":"0","endTime":"0","summary":"8月24日，康方生物盘中上涨3.49%，报92.3港元，成交额8182.51万港元。此外，公司自主研发的AK157d1近日获准开展实体瘤I期临床试验，使其差异化ADC管线扩充至三款，管线深度进一步增强。机构普遍维持买入评级，覆盖机构平均目标价170.79港元，较当前股价存在较大上行空间。此前股价于上一交易日回落近4%，短期超卖后叠加业绩预期催化，资金出现回补迹象。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康方生物上涨，业绩与ADC管线双催化","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661244437","title":"【券商聚焦】交银国际：中国内地mRNA疫苗产业整体低估严重","url":"https://stock-news.laohu8.com/highlight/detail?id=2661244437","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661244437?lang=zh_cn&edition=full","pubTime":"2026-08-24 09:18","pubTimestamp":1787534313,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，Moderna与默沙东共同宣布，intismeran联合K药辅助治疗IIB-IV期黑色素瘤的III期INTerpath-001研究达主要终点 。该机构认为，中国内地mRNA疫苗企业正处于全球公共卫生事件后的低谷期，产业整体低估严重，但海外可比产品的研发成功和适应症领域的拓展有望推动投资情绪和估值修复。此外，康希诺、智飞生物/沃森生物/康华生物等布局mRNA技术、处于估值底部的疫苗企业也值得持续关注。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1989096","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU0561508036.HKD","LU0880133367.SGD","LU1303224171.USD","LU1242518931.SGD","LU0516423174.USD","01177","09926","LU0979878070.USD","MRNY","01093","LU1226287792.SGD","LU0348766576.USD","06185","09995","LU1688375341.USD","LU0307460666.USD","LU0359201612.USD","LU0828237510.HKD","LU0588546209.SGD","LU0516422366.SGD","BK1191","LU1794554557.SGD","KCE","03329","BK1588","BK1576","01801","06160","BK1589","SG9999002562.SGD","02142","09688","LU2097828557.USD","LU0181495838.USD","KURE","01877","BK1147","LU0067412154.USD","02616","LU1008478684.HKD","MRNX","LU0043850808.USD","LU0320764599.SGD","LU1960683339.HKD","LU0244354667.USD","LU0348767384.USD","LU0417516571.SGD","LU0228659784.USD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135052836","title":"康方生物AK157d1（B7-H3 ADC）获准开展实体瘤I期临床，管线再添第三款差异化ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=1135052836","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135052836?lang=zh_cn&edition=full","pubTime":"2026-08-21 13:31","pubTimestamp":1787290277,"startTime":"0","endTime":"0","summary":"康方生物自主研发的AK157d1已获准开展实体瘤I期临床试验。这一进展标志着该公司在抗体偶联药物领域又落一子，使其差异化ADC管线扩充至三款。AK157d1靶向B7-H3，该靶点在多种实体瘤中高表达，被视为极具潜力的抗肿瘤治疗靶点。此次获批，意味着康方生物在ADC赛道的布局进一步深化。值得注意的是，B7-H3 ADC赛道竞争日趋激烈。随着I期试验的启动，AK157d1的安全性、耐受性及初步疗效数据将成为下一步关注的焦点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0540923850.HKD","LU0417516571.SGD","LU0348784397.USD","IE00B5MMRT66.SGD","KURE","LU0561508036.HKD","LU2476274720.SGD","09926","LU0348827113.USD","LU0348767384.USD","LU0348735423.USD","LU0348766576.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348783233.USD","BK1574","LU1720050803.USD","LU2476274308.USD","BK1161","LU1794554557.SGD","LU2778985437.USD","LU0634319403.HKD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU1961090484.USD","LU2488822045.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168070938","title":"异动解读｜康方生物盘中下跌3.41%，前日板块集体暴涨后获利回吐压力再现","url":"https://stock-news.laohu8.com/highlight/detail?id=1168070938","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168070938?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:14","pubTimestamp":1787278443,"startTime":"0","endTime":"0","summary":"8月21日，康方生物盘中下跌3.41%，报90.7港元，成交额4.24亿港元。消息面上，公司前一交易日随港股创新药板块集体走强而大涨超9%，当日板块内中国生物制药涨超20%、石药集团涨超16%，康方生物涨超11%。短期急速拉升后获利资金再度兑现离场。当日生物科技板块表现分化，百济神州跌1.58%，康希诺生物跌11.79%，板块整体承压。公司将于8月27日发布中期业绩，市场对依沃西放量节奏的关注度持续升温。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"康方生物回落，获利盘兑现压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":0.0777},{"period":"1month","weight":0.0542},{"period":"3month","weight":-0.1431},{"period":"6month","weight":-0.0533},{"period":"1year","weight":-0.3554},{"period":"ytd","weight":-0.1044}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0101},{"period":"3month","weight":0.0152},{"period":"6month","weight":-0.04},{"period":"1year","weight":0.0144},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家致力于研究、开发、生产及商业化让全球病人可负担的抗体药的投资控股公司。该公司在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域。该公司的产品主要包括有用于肿瘤领域的开坦尼（卡度尼利，PD-1/CTLA-4）、依达方（依沃西，PD-1/VEGF）、莱法利（AK117，CD47）、普络西（AK109，VEGFR-2）、安尼可（派安普利，PD-1）、科泰莱（塔戈利单抗，PD-L1）和用于代谢及自免领域的伊喜宁（伊努西单抗，PCSK9）、爱达罗（依若奇单抗，IL-12/IL-23）、古莫奇单抗（AK111，IL-17）。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.333333,"avgChangeRate":0.019031},{"month":3,"riseRate":0.5,"avgChangeRate":0.006875},{"month":4,"riseRate":0.833333,"avgChangeRate":0.041517},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.021305},{"month":6,"riseRate":0.571429,"avgChangeRate":0.077852},{"month":7,"riseRate":0.571429,"avgChangeRate":0.084887},{"month":8,"riseRate":0.571429,"avgChangeRate":0.004378},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}